Acceleron Pharma Inc (NASDAQ:XLRN) target price raised to $46.00, reported today by BTIG Research
- Updated: September 17, 2016
BTIG Research upped the price target of Acceleron Pharma Inc (NASDAQ:XLRN) to $46, reporting a possible upside of 0.49%.
On 4/27/2016, Barclays Capital reported on Acceleron Pharma Inc(NASDAQ:XLRN) upped the target price from $0.00 to $40.00 that suggested an upside of 0.30%.
Boasting a price of $30.77, Acceleron Pharma Inc (NASDAQ:XLRN) traded 2.98% higher on the day. With the last close down 10.23% relative to the 200-day moving average, compared with the S&P 500 which has fallen -0.01% over the date range. The company has registered a 50-day average of $31.35 and two hundred day average of $31.31. 419,817 shares of Acceleron Pharma Inc exchanged hands, up from ann average volume of 273,517
Recent Performance Graphic:
Acceleron Pharma Inc has a 52 week low of $21.93 and a one-year high of $50.86 and has a market cap of $0.0.
A total of 9 brokerages have issued a report on XLRN. Four firms rate the company a strong buy, four analysts rate the company a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the stock as sell with an average target stock price of $47.33
Brief Synopsis About Acceleron Pharma Inc (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, and which is being evaluated in Phase I studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.